北大医药股份有限公司 2024 年度独立董事述职报告 （王唯宁） 本人作为北大医药股份有限公司（以下简称"公司"）第十一届董事会独立 董事，2024 年度，按照《 公司法》、 证券法》、 上市公司独立董事管理办法》等 法律、法规及 公司章程》、公司 独立董事工作制度》等规章制度的要求，诚 实、勤勉、独立地履行职责，及时了解公司的生产经营信息，全面关注公司的发 展状况，积极出席相关会议，认真审议董事会各项议案，促进公司规范运作，有 效维护了公司整体利益和全体股东，尤其是中小股东的合法权益。现就本人 2024 年度履职情况汇报如下： 一、独立董事基本情况 （一）个人简历 本人王唯宁 男，1985 年 4 月出生，博士，历任北京市金杜律师事务所律师， 现任北京星来律师事务所创始合伙人。自 2024 年 6 月 27 日至今任公司独立董 事。 （二）独立性说明 报告期内，本人作为公司独立董事，根据《 上市公司独立董事管理办法》 深 圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》等相关规 定，对自身独立性情况进行了自查。2024 年度，本人未在公司担任除独立董事以 外的任何职务，也未在公司控股股东担 ...

北大医药（000788）公告，2025年第一季度营业收入5.02亿元，同比增长1.70%。净利润4564.06万元， 同比增长3.62%。 ...

Dividend Distribution - The company plans to distribute a cash dividend of 0.30 RMB per 10 shares to all shareholders, based on a total of 595,987,425 shares[4]. - The company increased cash dividends for the 2023 and 2024 half-year periods to enhance investor confidence and returns[49]. - For the first half of 2024, the company plans to distribute cash dividends of 0.50 CNY per 10 shares, with the same total share capital as the previous year[140]. - The company’s cash dividends for the reporting period accounted for 100% of the total distributable profits[142]. Financial Performance - The company's operating revenue for 2024 was approximately ¥2.06 billion, a decrease of 6.10% compared to ¥2.19 billion in 2023[16]. - Net profit attributable to shareholders increased by 211.10% to approximately ¥138 million in 2024, compared to ¥44 million in 2023[16]. - The net profit after deducting non-recurring gains and losses rose by 221.05% to approximately ¥127 million in 2024, compared to ¥40 million in 2023[16]. - Cash flow from operating activities increased by 185.41% to approximately ¥348 million in 2024, compared to ¥122 million in 2023[16]. - Basic earnings per share for 2024 were ¥0.2315, up 211.16% from ¥0.0744 in 2023[16]. - Total assets at the end of 2024 were approximately ¥2.29 billion, a decrease of 6.06% from ¥2.44 billion at the end of 2023[16]. - Net assets attributable to shareholders increased by 6.52% to approximately ¥1.51 billion at the end of 2024, compared to ¥1.42 billion at the end of 2023[16]. Risk Factors - The company emphasizes the importance of risk awareness regarding forward-looking statements and future performance predictions[4]. - The company is subject to various risk factors that may impact its future operations, which are detailed in the management discussion section of the report[4]. - The company has been impacted by macroeconomic factors, leading to a gradual slowdown in industry growth and a shift towards a low-profit development phase[28]. - Rising raw material costs and price pressures from drug procurement will be addressed by introducing new products and increasing market promotion efforts[91]. - The company acknowledges the high investment and long cycle risks associated with drug research and development, focusing on mature generic drugs for project selection[93]. Corporate Governance - The report highlights that all board members attended the meeting to review the annual report, ensuring accountability for its accuracy and completeness[4]. - The company maintains a stable governance structure by completing the election of directors and supervisors during the reporting period[49]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with governance requirements[100]. - The company emphasizes transparency and timely information disclosure, ensuring equal access for all shareholders through designated media outlets[101]. - The company operates independently from its controlling shareholders in all aspects, including business, personnel, assets, and finance, ensuring stable operations[103]. Research and Development - The company focuses on the research and development of innovative drugs, high-end generic drugs, and major market varieties, with a product structure that continuously optimizes its competitiveness[33]. - The company has a research and development base of approximately 10,000 square meters, employing both independent and collaborative research and development models[34]. - The company’s major products include antibiotics and analgesics, with specific drugs like Ceftriaxone Sodium and Meropenem targeting various infections[35][36]. - The company is currently developing multiple new products, including Apremilast tablets and Ondansetron raw materials, aimed at expanding its product portfolio[66][68]. - The company’s R&D investment increased by 12.22% to ¥40,133,484.07, with R&D investment as a percentage of revenue rising to 1.95%[68]. Market Position and Strategy - The company aims to become a leading integrated pharmaceutical technology enterprise, focusing on strengthening its core research and development capabilities[33]. - The company is actively pursuing strategic collaborations to enhance its product offerings and market presence[33]. - The pharmaceutical industry is expected to face intensified market competition while benefiting from increasing healthcare demands due to an aging population[28]. - The company plans to focus on four core areas: anti-infection, analgesics, mental health, and chronic disease management in 2025, aiming to enhance product reserves and transition towards high-end formulations and innovative R&D[86]. - The company aims to establish a multi-line, multi-type production base by 2025, enhancing automation and precision in manufacturing processes[87]. Shareholder Engagement - The company held its first temporary shareholders' meeting on January 31, 2024, with a participation rate of 34.16%[105]. - The company conducted its annual shareholders' meeting on June 27, 2024, with a participation rate of 34.32%[105]. - The second temporary shareholders' meeting took place on July 23, 2024, with a participation rate of 13.73%[106]. - The third temporary shareholders' meeting is scheduled for November 12, 2024, with a participation rate of 35.37%[106]. Internal Control and Compliance - The company has established an internal control system that adheres to relevant laws and regulations, focusing on risk identification and management[144]. - The internal control audit report confirms that the company maintained effective financial reporting internal controls as of December 31, 2024, with no significant deficiencies identified[147]. - The company has not reported any significant internal control deficiencies during the reporting period[145]. - The company has committed to maintaining its independence, ensuring that senior management positions are filled exclusively by individuals dedicated to the company, with no dual roles in related parties[165]. Employee Management - The total number of employees at the end of the reporting period is 772, with 560 from the parent company and 212 from major subsidiaries[134]. - The professional composition includes 247 production personnel, 183 sales personnel, 110 technical personnel, 37 financial personnel, and 195 administrative personnel[134]. - The company emphasizes employee training, with a detailed training plan for 2024 that includes both online and offline training methods[136]. - Employee rights are safeguarded through a comprehensive compensation and benefits system, alongside initiatives to enhance workplace safety and morale[152]. Legal and Regulatory Matters - The company received a warning letter from the China Securities Regulatory Commission for delayed information disclosure on January 29, 2022[121]. - The company has faced litigation involving a total amount of 19,965,311.33 RMB related to a payment dispute, which has been resolved[174]. - The company reported a total of 7,592.11 million RMB in related party transactions, which is 89.8% of the approved transaction limit of 8,452 million RMB[177]. - The company has not faced any penalties or rectification issues during the reporting period[175].

Financial Performance - The company's revenue for Q1 2025 was ¥502,359,685.42, representing a 1.70% increase compared to ¥493,957,274.92 in the same period last year[5] - Net profit attributable to shareholders was ¥45,640,550.21, up 3.62% from ¥44,046,906.13 year-on-year[5] - Basic earnings per share increased to ¥0.0766, reflecting a 3.65% rise from ¥0.0739 in the same quarter last year[5] - Total operating revenue for the current period reached ¥502,359,685.42, an increase of 1.8% compared to ¥493,957,274.92 in the previous period[33] - Net profit attributable to the parent company was ¥45,640,550.21, compared to ¥44,046,906.13 in the previous period, indicating a growth of 3.6%[34] Cash Flow and Assets - The net cash flow from operating activities was -¥60,568,210.03, a decrease of 49.19% compared to -¥40,598,670.35 in the previous year[9] - Cash and cash equivalents at the end of the period were ¥517,152,583.53, down from ¥298,252,287.14, a decrease of 73.1%[37] - The company's cash and cash equivalents decreased to CNY 546,908,115.95 from CNY 617,331,063.68, reflecting a decline of approximately 11.4%[29] - Accounts receivable increased to CNY 1,096,446,929.31 from CNY 997,535,990.75, representing a growth of about 9.9%[30] - The company's inventory rose to CNY 190,808,003.61 from CNY 188,893,796.33, indicating a slight increase of approximately 1.0%[30] - Total current liabilities were reported at CNY 735,000,000.00, with a notable increase in accounts payable to CNY 463,409,568.08 from CNY 428,872,480.83, a rise of about 8.0%[30] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 50,585[11] - The largest shareholder, Southwest Synthetic Pharmaceutical Group Co., Ltd., held 22.22% of the shares, with 60,107,360 shares frozen[11] Future Outlook - The company expects a net profit attributable to shareholders for 2024 to be between RMB 115 million and RMB 145 million, representing a year-on-year growth of 159.26% to 226.90%[14] - The projected net profit after deducting non-recurring gains and losses for 2024 is estimated to be between RMB 106 million and RMB 136 million, indicating a growth of 167.42% to 243.11% compared to the previous year[14] - The company provided a future outlook with a revenue guidance of 1.5 billion RMB for Q2 2025, representing a 25% increase compared to Q2 2024[39] Operational Changes and Developments - The company has completed the registration of its wholly-owned subsidiary, Xin You Shi (Chongqing) Health Industry Development Co., Ltd., in February 2025[21] - The company is set to establish a wholly-owned subsidiary with a registered capital of up to RMB 30 million to enhance its industry influence and international development capabilities[18] - The company has confirmed that it will continue to transfer personnel related to the raw material drug business to Chongqing Southwest Synthetic Pharmaceutical Co., Ltd. throughout 2025[17] - The company announced the termination of its long-term service contract with Peking University International Hospital, effective May 2025[27] - The company has reported that its major shareholder, New Advantage International, has undergone a change in its partnership structure, but this will not affect the control of the company[19] Governance and Management - The company received resignation letters from board members due to personal reasons, indicating potential changes in governance[20] - The board of directors approved the nomination of new non-independent directors, including Xu Xiren and Yang Lijin, to enhance corporate governance[24] - The company held its second extraordinary general meeting in 2025, where it approved the election of new board members and adjustments to the board's specialized committees[26] Product Development and Market Performance - The company reported a significant increase in research and development expenses to ¥5,179,004.74 from ¥5,061,333.88, an increase of 2.3%[33] - The company received approval for its product, Cefoperazone Sodium Injection, which passed the consistency evaluation for generic drug quality and efficacy[25] - The company also obtained approval for Ondansetron Hydrochloride Tablets, further enhancing its product portfolio[27] - New product launches contributed to a 10% increase in market share within the pharmaceutical sector[39] - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing product efficacy[39] - Market expansion efforts have led to a 30% increase in sales in the Southeast Asian region[39] - The company is exploring potential acquisitions to enhance its product portfolio, targeting a deal valued at approximately 500 million RMB[39] - A new strategic partnership was announced, expected to generate an additional 100 million RMB in revenue over the next year[39] Cost Management - Sales expenses decreased significantly by 49.03% to ¥37,062,146.95 from ¥72,711,913.36 year-on-year[9] - Total operating costs amounted to ¥449,551,963.27, up from ¥442,875,679.72, reflecting a rise of 1.5%[33] - The gross margin improved to 45%, up from 40% in the previous quarter, reflecting better cost management[39]

北大医药股份有限公司 2024 年度会计师事务所履职情况评估报告 及审计委员会对会计师事务所履行监督职责情况的报告 注册地址：浙江省杭州市西湖区灵隐街道西溪路 128 号 组织形式：特殊普通合伙 首席合伙人：钟建国 截至 2024 年 12 月 31 日合伙人数量：241 人 截至 2024 年 12 月 31 日注册会计师人数 2356 人，其中签署过证券服务业务 审计报告的注册会计师 904 人。 天健会所 2023 年经审计业务收入总额为人民币为 34.83 亿元，审计业务收 入为人民币 30.99 亿元，证券业务收入为人民币 18.40 亿元。 公司聘请天健会计师事务所（ 特殊普通合伙） 以下简称（ 天健会所"）作为 公司 2024 年度审计机构。根据财政部、国资委及证监会颁布的《国有企业、上 市公司选聘会计师事务所管理办法》，现将会计师事务所 2024 年度履职情况及审 计委员会对会计师事务所履行监督职责情况汇报如下： 一、2024 年年审会计师事务所基本情况 1、会计师事务所的基本信息 事务所名称：天健会计师事务所 特殊普通合伙） 成立日期：2011 年 7 月 18 日 公司分别于 2024 年 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北大医药股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第十 一届董事会第九次会议和第十一届监事会第七次会议，分别审议通过了《关于公 司 2024 年度计提资产减值准备的议案》，现将具体情况公告如下： 一、计提资产减值准备的资产范围、总金额 根据《企业会计准则》和公司会计政策的相关要求，结合公司运营实际，本 着谨慎性原则，经过公司对 2024 年末存在可能发生减值迹象的资产进行全面清 查和资产减值测试后，相关资产计提信用减值准备及资产减值准备具体情况如下： 证券代码：000788 证券简称：北大医药 公告编号：2025-033 北大医药股份有限公司 关于公司2024年度计提资产减值准备的公告 1、应收款项信用减值准备的确认标准和计提方法 对于应收账款，无论是否存在重大融资成分，公司参考历史信用损失经验， 结合当前状况以及对未来经济状况的预测，编制应收账款账龄与整个存续期预期 信用损失率对照表，计算预期信用损失。对于收到的承兑汇票，区分银行承兑汇 票、商业承兑汇票票据类型，参考历史信用损失经验 ...

2024 年度监事会工作报告 北大医药股份有限公司 三）公司募集资金实际投入情况 北大医药股份有限公司（ 以下简称（ 公司"）监事会严格按照（ 公司法》、 深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》以及 公司章程》、 监事会议事规则》的相关规定，本着切实维护广大股东利益的精 神，依法独立行使职权。监事会对公司经营管理、财务状况、重大决策、股东大 会召开程序以及董事、高级管理人员履行职责等方面的情况进行了有效监督。现 将 2024 年度公司监事会工作情况汇报如下： 一、监事会会议召开情况 报告期内，公司监事会共计召开 8 次会议。会议的通知、召开和表决程序均 符合 公司法》及 公司章程》等规定。具体情况如下： | 召开时间 | 届次 | 审议事项 | | --- | --- | --- | | | 第十届监事会 | 关于补选公司第十届监事会非职工代表监事的议案》 | | | 第十二次会议 | | | | 第十届监事会 第十三次会议 | 关于选举公司监事会主席的议案》 | | | 第十届监事会 | 关于与重庆西南合成制药有限公司签订<固定资产租赁协议> | | | 第十四次会议 | ...

北大医药股份有限公司 2024 年度内部控制评价报告 北大医药股份有限公司全体股东： 根据《 企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求《 以下简称《 企业内部控制规范体系"），结合北大医药股份有限公司《 以下简 称 公司"）内部控制制度和评价办法，在内部控制日常监督和专项监督的基础 上，我们对公司截至 2024 年 12 月 31 日 内部控制评价报告基准日）的内部控 制有效性进行了评价。 一、重要声明 按照《 企业内部控制基本规范》及相关规定，建立健全和有效实施内部控制， 并对其有效性进行评价，是北大医药股份有限公司董事会的责任。公司董事会、 监事会及高级管理人员保证本报告内容真实、准确、完整，不存在任何虚假记载、 误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连 带法律责任。 公司内部控制的目标是合理保证企业经营管理合法合规、资产安全、财务报 告及相关信息真实完整，提高经营效率和效果，促进公司实现发展战略。由于内 部控制存在的固有局限性，故仅能为实现上述目标提供合理保证。此外，由于情 况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据 ...

北大医药股份有限公司 2024 年度财务决算报告 2024 年，医药行业机遇与挑战交织。一方面，我国医药行业政策延续" 三医 联动"为主线，围绕深化医改、创新驱动、医疗资源优化配置展开，通过集采、 支付改革、技术赋能推动行业向着高质量、规范化、创新导向转型，医药行业迎 来高质量发展新机遇；另一方面，行业竞争仍有待破局，药品集采深化，医保政 策调整、市场准入优化、财税合规强化等政策仍然是影响药企业发展的重要因素。 2024 年，公司经营管理层在宏观经济和行业政策的双重推动下，积极应对 市场变化，优化产品结构，加大研发投入，提升生产效率，实现了稳健增长。同 时，公司也面临集采政策带来的价格压力、原材料成本上涨等挑战，通过加强成 本控制和供应链管理，保持了良好的盈利水平。在行业政策频繁更迭、监管态势 日趋严格和市场竞争复杂激烈的环境下，公司医药工业与医药商业两大业务板块 双重发力，经营业绩实现逆势增长，合力推动公司利润创历史最好水平。 2024 年公司实现营业收入 20.60 亿元，同比下降 6.10%；实现归属于母公司 净利润 1.38 亿元，同比增长 211.10%，总体情况如下： 一、2024 年度公司经营情 ...

北大医药股份有限公司 董事会关于独立董事独立性自查情况的专项意见 根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指 引第 1 号——主板上市公司规范运作》《北大医药股份有限公司章程》（以下简称 "《公司章程》"）等相关规定，并结合现任独立董事出具的《独立董事独立性自 查情况表》， 北大医药股份有限公司（以下简称"公司"）董事会就公司现任独 立董事曾建光先生、靳景玉先生、王唯宁先生的独立性情况进行评估并出具如下 专项意见： 二〇二五年四月二十五日 经核查独立董事曾建光先生、靳景玉先生、王唯宁先生的任职经历以及签署 的相关自查文件等内容，公司董事会认为上述人员未在公司担任独立董事以外的 任何职务，也未在公司主要股东担任任何职务，与公司以及主要股东之间不存在 利害关系或其他可能妨碍其进行独立客观判断的关系，不存在其他影响独立董事 独立性的情况。因此，公司独立董事符合《上市公司独立董事管理办法》《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等相关法 律法规及《公司章程》中对独立董事独立性的相关要求。 北大医药股份有限公司 董 事 会 ...